Although the fraction of metastatic breast cancer patients with long-term tumor remission is small, we provide evidence that HER2 positive patients who initially respond to palliative treatment with trastuzumab can achieve a long-term tumor remission of several years. The gene discussed is ERBB2; the disease is neoplasm.